Your Fitness Feed, Finally Focused

Oral GLP-1 pills (orforglipron/Foundayo, aleniglipron, UBT251, Wegovy pill, Eli Lilly) with FDA approvals

Oral GLP-1 pills (orforglipron/Foundayo, aleniglipron, UBT251, Wegovy pill, Eli Lilly) with FDA approvals

Key Questions

What are oral GLP-1 weight loss pills?

Oral versions like orforglipron (Foundayo), aleniglipron, UBT251, and Wegovy pill mimic GLP-1 for appetite control and 12-16% weight loss without injections. FDA approvals accelerate access. Pair with RT and 1.6-3.1g/kg protein to preserve muscle.

Which oral GLP-1s have FDA approval?

Eli Lilly's orforglipron/Foundayo ($25/mo, 12.4% WL), speedy FDA nod for obesity pill, and Oral Wegovy (out Jan, $149/mo starter, 12-14% WL). Aleniglipron and UBT251 in Ph2 with ~15-16% WL. Production scaling for availability.

What weight loss results do oral GLP-1s achieve?

Ph2 trials show aleniglipron/UBT251 ~15-16%, Wegovy pill 9mg 15lb, orforglipron 12.4%, vs Zepbound 20%. Maintenance and lean preservation require RT/nutrition. Top patients combine with habits for best outcomes.

What are the advantages of oral GLP-1s over injections?

Pills offer cost/convenience (no needles/fridge), with Americans preferring them for accessibility. Foundayo ships now insured; Wegovy pill cheaper long-term. Safe profile similar to injectables.

How much do oral GLP-1 weight loss pills cost?

Foundayo $25/mo insured, Oral Wegovy $149/mo starter. Lower than many injectables, with scaling production for affordability. Access improves with FDA nods.

Ph2 alenig15–16%/UBT25115-16%/Wegovy pill 9mg 15lb/Eli Lilly FDA orforglipron/Foundayo $25/mo 12.4% WL insured ships now speedy 15%+/Oral Wegovy out Jan $149/mo starter 12-14%WL vs Zep20% no shots/next-gen; Eli Lilly scaling production post-approval/Novo Wegovy pill explosive launch drawing new patients. Vs inj/safe/maint/lean Qs—reinforce RT/nutr(1.6–3.1g/kg prot/sarc). New FDA approval accelerates access; pills win cost/convenience no needles/fridge; fresh FDA nod to new WL pill.

Sources (7)
Updated Apr 8, 2026